|
|
|
|
| |
|
| Beriglobin P: |
|
| |
|
 |
|
 |
Registration No.: |
T/30.2/608 2ml
T/30.2/609 5ml |
|
|
| |
|
|
Beriglobin P is beneficial for anybody
at increased risk or lowered resistance. The advantages
of Beriglobin P are:
- Beriglobin P is the only
gammaglobulin which is manufactured from plasma
which is subjected to P.C.R. (Polymerase Chain
Reaction) testing. It is tested for HAV, HBV, HCV,
HIV and Parvo B 19. P.C.R.Testing reduces the window
period in the case of HCV from 82 to 23 days, HBV 56
to 31 days and HIV from 22 to 11 days.
- Beriglobin P contains antibodies
against a multitude of viruses and bacteria.
- Plasma from all donors is kept
under quarantine for at least sixty days. From
first-time donors it is kept for six months,
therefore the window period is eliminated.
- The plasma used in the production
of Beriglobin P is pasteurised. Pasteurisation
inactivates enveloped and certain non-enveloped
viruses.
- Treatment of chronic bronchitis
with Beriglobin P (10ml stat, 5ml 4 weeks later and
another 5ml 4 weeks later for adults and 5ml stat,
2ml 4 weeks later and another 2ml 4 weeks later for
children), resulted in complete freedom of
recidivation in 69% of cases as well as an
improvement in the general state of health.1
- Treatment of recidivating
pyelonephritis with Beriglobin P and antibiotics
produced very good results in 65,9% of cases.1
- Administration of Beriglobin P
reduces the risk of Hepatitis A from 3,1% to 1,75%.
(0.05ml per kg
body weight repeated after three months).2
COMPOSITION Each 1 ml
contains:
Human Immunoglobulin 160mg (antibodies to hepatitis A at
least 100 iu)
1. Chronic infections Dr. E
Plassmann, Medical Practice XXXV Year no. 91 p 2788/2790
12 November 1983.
2. Gerhard Wiedermann et al Hepatitis Prophylaxis with
Immunoglobulin for the Austrian United Nations Battalion
Health Information
Leaflet 21 No. 26 of 22 December 1978.
|
|
| |
|
|
Preface to the
second edition: |
|
Preface
to the first edition: |
| |
|
|
|
Only by
complementing each other can science and
experience form the basis of medical practice.
Therapeutic experience is vital in medicine and
is the only foundation for research and science.
This experience is also necessary for evaluating
results obtained by scientific methods.
Furthermore, medical experience is needed in
handling scientific knowledge, if this is to be
implemented on a practical level.
In view of
this we have taken it upon ourselves to report
on the results obtained to date with Berigobin®
S in extended indications, as well as on new
findings in the therapeutic immunology. In
addition to the treatment carried out
successfully for eight years with Beriglobin®
in hay fever, allergic bronchial asthma,
opportunistic infections of the respiratory and
urinary tracts, prophylaxis of infection and
treatment of infections in cancer patients, we
have included prophylaxis of infection in
geriatrics and passive immunization against
viral hepatitis A with Beriglobin®
S, which should be expressly recommended for the
protection of travellers in an age of increasing
tourism. The introduction of human
immunoglobulins into therapy and prophylaxis
has, in the course of over 30 years, proved to
be a reliable tool in routine practice. Drugs
that are effective and have virtually no side
effects must be promoted for use in preventive
medicine and for therapeutic measures,
particularly at present when economies and
cost-cutting in the health sector are the order
of the day.
In am indebted to many of my colleagues at home
and abroad for their ideas and encouragement.
Göppingen, May 1988
H. Ardjah
|
|
“Every disease
penetrates deep into the immune system.
Consequently, no therapy is successful without
the support of the immune system” (H.v. Kress).
The treatment
of hay fever, allergic bronchial asthma and
opportunistic infections is still fraught with
problems despite the major advances that have
been made in drug therapy and
hyposensitization. Opportunistic infections of
the respiratory tract, which often lead to
chronic bronchitis and chronic cor pulmonale,
allergic alveolitis and allergic bronchial
asthma with immunological pathogenesis, make it
necessary for us to use multiple therapy in
clinical practice on a regular basis.
Recurring
cystitis and cystopyelitis with late
complications cannot be completely and
successfully controlled as independent disorders
or when they occur with other infections in
cancer patients even with the antibiotic or
chemotherapeutic measures used hitherto.
According to
reports in the literature to date and our own
experience, treatment with immunoglobulin of all
the problems outlined above is effective in the
vast majority of patients, economical, well
tolerated and therefore to be recommended.
The repeated
administration of immunoglobulin in untreated
hay fever or in patients who have failed to
respond to hyposensitization, even in cases of
manifest disease, is effective in over 70% of
patients.
The simplicity
of the method and the natural character of the
medication provide doctors in non-hospital
practice with an effective tool for the
treatment of the problem indications outlined
above.
After a brief
introduction to immunology, an attempt is made
to demonstrate the many years’ experience in the
treatment of these problems with immunoglobulin
by of individual examples.
Göppingen, May 1988
H. Ardjah
|
|
|
| |
|
| Preface
to the third
edition: |
|
| |
|
|
According to
international scientists, the most important health
problems in the year 2000 and beyond will result from
the changing structure of the population and an
associated change in the disease process. With the
increase in life expectancy, chronic and degenerative
disorders will achieve ever greater importance. It is
assumed that the average life expectancy in the year
2000 will be about 75 years for the male population in
Germany and about 82 years for women.
Knowledge obtained
from present research indicates that the number of
patients with chronic disorders will continue to
increase. In particular, rheumatic diseases are likely
to represent one of the major problems in the future,
despite the extensive therapeutic methods that are
already available. In addition, there is still room for
improvement in the prophylaxis and treatment of
infectious diseases such as herpes zoster, which
frequently occurs in middle and advanced age.
Analysis of routine
prescriptions in everyday clinical practice shows that
analgesics and antirheumatic drugs occupy first place
among the prescriptions for drugs, in line with the
increase in chronic rheumatic disorders.
Both the therapeutic
interventions in the field of rheumatology and the
polysymptomatic treatment of herpes zoster can be
costly, inadequate and fraught with complications.
The spectrum of
chronic disorders that can be treated successfully has
been extended with our new treatment for rheumatic
disorders and herpes zoster. Patients with rheumatic
polyarthropathy or chronic recurrent herpes zoster were
treated with Beriglobin®
S according to the recommended regimen, which meant that
other drugs such as analgesics could be totally or
partially omitted. Above all, besides being effective
and economical, gammaglobulin therapy offers a
practicable alternative with few complications in the
treatment of rheumatoid arthritis and herpes zoster.
I am indebted to Mrs
B. Leitsch, my scientific colleague of many years’
standing, and to Dr. Lässig for their generous support
and co-operation.
Göppingen, January 1992
H. Ardjah
|
|
| |
|
 |
|
| |
|
|
The 46 patients in
group I were initially treated with 10 ml Beriglobin®
S i.m. Other measures were avoiding touching the spots,
local symptomatic and drying-out treatment and, if
necessary, pain control. Parameters for assessing the
treatment with Beriglobin® S were the persistence of the
eruptions, observed from the appearance of the
herpetiform vesicles until the scabs fell off, the
occurrence of pain and if necessary the administration
of drugs, e.g. analgesics, and elimination of any local
smarting or itching or a reduction in the symptoms as a
whole. The vast majority of the patients in group I,
namely 32 out of 46, 19 of whom were women and 13 men
reported a marked reduction in pain and an improvement
in their general wellbeing just 1 - 3 days after
receiving 10 ml Beriglobin®
S. These and the other 14 patients in the group which
was given Beriglobin® S
showed a rapid improvement in general wellbeing as well
as freedom from pain and healing of the affected skin
areas after 1 - 2 further treatments with Beriglobin®
S. These observations were noted in detail, recorded and
included in the statistics. Parallel to this, the
parameters freedom from
pain, relief from smarting and itching, duration of
eruptions and impairment of general wellbeing were
observed during the multiple symptomatic therapy
available hitherto.
|
|
| |
|
 |
|
| |
|
|
The drugs used in group II were:
acyclovir for antiviral therapy, analgesics (e.g.
paracetamol) for the treatment of pain and, in isolated
cases, neuroleptics and antidepressants. Depending on
the clinical picture and course of the disease, local
therapy was carried out, for example with zinc sulphate
paste. Apart from the symptomatic effect, for example on
the paid or skin eruptions, this treatment had no effect
worth mentioning on the course and duration of cases of
acute and chronic zoster neuralgia. All the typical
zoster symptoms ranging from the impairment of general
wellbeing, local reactions and pruritus to general
psychomotor agitation were pronounced in the group of
patients receiving only symptomatic therapy. Whereas the
skin areas in the patients in group I healed and were
almost without symptoms within 10 - 18 days, the
symptomatic measures had to be continued in the control
group for 4 weeks or sometimes even longer, depending on
the age of the patients, with a marked restriction in
general wellbeing. Antibiotic treatment had to be used
in 8 patients because of concomitant febrile infections
in the bronchopulmonary and urogenital region The older
the patients, the more frequently these complications
were observed. Moreover it was noticeable that none of
the patients in group I suffered from concomitant
febrile disorders.
|
|
| |
|
|
Skin Symptoms:
The clinical picture starts with the rash typical of
herpes zoster, localized in one or two neighbouring
dermatomes on one side of the body. The herpetiform
vesicles are mainly filled with pus or blood, usually
undergo necrosis and as a rule leave scars or slight
pigmentation of the affected areas of skin.
|
|
| |
|
 |
|
| |
|
|
Depending on the body weight,
treatment with Beriglobin®
S was started with 10 ml or in patients of low body
weight with 5 ml initially i.m. and was continued
according to the clinical picture and the extent of the
symptoms reported by the patients. Where there were pain
and eruptions, a second injection was administered after
5 - 7 days. Where necessary, a third injection of 5 ml
Beriglobin® S
i.m. was given at the end of a further 14 days. The
control group was not treated with Beriglobin®
S. It received the usual local and analgesic therapy.
|
|
| |
|
 |
|
| |
|
 |
|
| |
|
|
It is striking that most of the
symptoms decreased as the eruptions subsided. As the
sensation of pain and pruritus vary according to the
individual, a uniform interpretation of these parameters
is possible to only a limited extent. The patients’
reports on the duration and severity of their symptoms
after the start of treatment are however informative
when both treatment groups are compared. They show more
rapid freedom from the symptoms in the immunoglobulin
group, with faster and in most cases complication-free
healing of the zoster. Pruritus and pain were not always
experienced jointly in both treatment groups. Some
patients complained only of pain and others only of
pruritus. Most of them reported both symptoms, however.
|
|
| |
|
|
|
| |
|
